These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 19934389

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature.
    Dell'Orto VG, Bianchetti MG, Brazzola P.
    J Clin Pharm Ther; 2013 Dec; 38(6):526-7. PubMed ID: 23981248
    [Abstract] [Full Text] [Related]

  • 3. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Dec; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC.
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract] [Full Text] [Related]

  • 6. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
    Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H.
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):564-7. PubMed ID: 20733517
    [Abstract] [Full Text] [Related]

  • 7. Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?
    Vlachaki E, Chatzinikolaou K, Bekiari E, Klonizakis F, Tsapas A.
    Angiology; 2011 May; 62(4):346-8. PubMed ID: 21306999
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT, Olin BR.
    Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
    [Abstract] [Full Text] [Related]

  • 9. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
    Wei HY, Yang CP, Cheng CH, Lo FS.
    Transfusion; 2011 May; 51(5):949-54. PubMed ID: 21077910
    [Abstract] [Full Text] [Related]

  • 10. The effects of deferasirox on renal, cardiac and hepatic iron load in patients with β-thalassemia major: preliminary results.
    Unal S, Hazirolan T, Eldem G, Gumruk F.
    Pediatr Hematol Oncol; 2011 Apr; 28(3):217-21. PubMed ID: 21083355
    [Abstract] [Full Text] [Related]

  • 11. Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy.
    Masera N, Rescaldani C, Azzolini M, Vimercati C, Tavecchia L, Masera G, De Molfetta V, Arpa P.
    Haematologica; 2008 Jan; 93(1):e9-10. PubMed ID: 18166775
    [No Abstract] [Full Text] [Related]

  • 12. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE, Hagemann TM.
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [Abstract] [Full Text] [Related]

  • 13. Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.
    Marano M, Bottaro G, Goffredo B, Stoppa F, Pisani M, Marinaro AM, Deodato F, Dionisi-Vici C, Clementi E, Falvella FS.
    Eur J Clin Pharmacol; 2016 Feb; 72(2):247-8. PubMed ID: 26403473
    [No Abstract] [Full Text] [Related]

  • 14. Acute renal failure and Fanconi syndrome due to deferasirox.
    Grangé S, Bertrand DM, Guerrot D, Eas F, Godin M.
    Nephrol Dial Transplant; 2010 Jul; 25(7):2376-8. PubMed ID: 20466673
    [Abstract] [Full Text] [Related]

  • 15. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ.
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [Abstract] [Full Text] [Related]

  • 16. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
    Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, Tabibian S, Bamedi T.
    Pediatr Hematol Oncol; 2013 Nov; 30(8):748-54. PubMed ID: 24134694
    [Abstract] [Full Text] [Related]

  • 17. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y, Turlin B, Ropert M, Cappellini MD, Porter JB, Giannone V, Zhang Y, Griffel L, Brissot P.
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [Abstract] [Full Text] [Related]

  • 18. Gastric ulcer in a child treated with deferasirox.
    Bauters T, Mondelaers V, Robays H, Hunninck K, de Moerloose B.
    Pharm World Sci; 2010 Apr; 32(2):112-3. PubMed ID: 20063122
    [Abstract] [Full Text] [Related]

  • 19. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 20. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V, Berdousi H, Gotsis E, Kattamis A.
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.